期刊
BIOMEDICINES
卷 8, 期 9, 页码 -出版社
MDPI
DOI: 10.3390/biomedicines8090294
关键词
IDH mutation; glioma; cancer; therapy resistance
资金
- Intramural Research Program of the National Institutes of Health, National Cancer Institute
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS003144] Funding Source: NIH RePORTER
Mutations in isocitrate dehydrogenase (IDH) are commonly observed in lower-grade glioma and secondary glioblastomas.IDHmutants confer a neomorphic enzyme activity that converts alpha-ketoglutarate to an oncometabolite D-2-hydroxyglutarate, which impacts cellular epigenetics and metabolism.IDH mutation establishes distinctive patterns in metabolism, cancer biology, and the therapeutic sensitivity of glioma. Thus, a deeper understanding of the roles of IDH mutations is of great value to improve the therapeutic efficacy of glioma and other malignancies that share similar genetic characteristics. In this review, we focused on the genetics, biochemistry, and clinical impacts ofIDHmutations in glioma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据